Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beryl L Manning-Geist

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Cancer|March 23, 2023
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapiesBeryl L Manning-Geist, Ryan M Kahn, David Nemirovsky, et al.
Gynecologic Oncology|June 28, 2024
Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilitiesBeryl L Manning-Geist, Mackenzie W Sullivan, Qin Zhou, et al.
Pharmacoepidemiology and Drug Safety|March 4, 2020
Validation of algorithms to identify adverse perinatal outcomes in the Medicaid Analytic Extract databaseMengdong He, Krista F Huybrechts, Sara Z Dejene, et al.
Gynecologic Oncology|July 16, 2023
Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary studyTiffany Y Sia, Beryl L Manning-Geist, Sarah Ehmann, et al.
Cancers|March 11, 2023
Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third RemissionBeryl L Manning-Geist, Sacha Gnjatic, Carol Aghajanian, et al.
Gynecologic Oncology|November 12, 2021
Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancerBeryl L Manning-Geist, Sushmita B Gordhandas, Dilip D Giri, et al.
Gynecologic Oncology|January 20, 2023
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide managementYing L Liu, Beryl L Manning-Geist, Andrea Knezevic, et al.
Transplantation and Cellular Therapy|February 3, 2022
Prospective Phase II Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bronchiolitis Obliterans Syndrome PathogenesisKirsten M Williams, Steven Z Pavletic, Stephanie J Lee, et al.
American Journal of Obstetrics and Gynecology|December 13, 2021
Risk factors for financial toxicity in patients with gynecologic cancerEmeline M Aviki, Beryl L Manning-Geist, Stefania S Sokolowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2022
Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical ProfilesBeryl L Manning-Geist, Ying L Liu, Kelly A Devereaux, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cancer|March 23, 2023
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapiesBeryl L Manning-Geist, Ryan M Kahn, David Nemirovsky, et al.
Gynecologic Oncology|June 28, 2024
Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilitiesBeryl L Manning-Geist, Mackenzie W Sullivan, Qin Zhou, et al.
Pharmacoepidemiology and Drug Safety|March 4, 2020
Validation of algorithms to identify adverse perinatal outcomes in the Medicaid Analytic Extract databaseMengdong He, Krista F Huybrechts, Sara Z Dejene, et al.
Gynecologic Oncology|July 16, 2023
Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary studyTiffany Y Sia, Beryl L Manning-Geist, Sarah Ehmann, et al.
Cancers|March 11, 2023
Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third RemissionBeryl L Manning-Geist, Sacha Gnjatic, Carol Aghajanian, et al.
Gynecologic Oncology|November 12, 2021
Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancerBeryl L Manning-Geist, Sushmita B Gordhandas, Dilip D Giri, et al.
Gynecologic Oncology|January 20, 2023
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide managementYing L Liu, Beryl L Manning-Geist, Andrea Knezevic, et al.
Transplantation and Cellular Therapy|February 3, 2022
Prospective Phase II Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bronchiolitis Obliterans Syndrome PathogenesisKirsten M Williams, Steven Z Pavletic, Stephanie J Lee, et al.
American Journal of Obstetrics and Gynecology|December 13, 2021
Risk factors for financial toxicity in patients with gynecologic cancerEmeline M Aviki, Beryl L Manning-Geist, Stefania S Sokolowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2022
Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical ProfilesBeryl L Manning-Geist, Ying L Liu, Kelly A Devereaux, et al.
Pageof 4